Current Edition


AstraZeneca and other lung cancer specialists join together to emphasize early screenings

If there is one strong message Camille Hertzka, AstraZeneca vice president and head of oncology, U.S. medical, wants people to take away from lung cancer …

Continue Reading →

Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failure

Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be …

Continue Reading →

Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?

Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But …

Continue Reading →
lung cancer

AZ teams up with G1 on lung cancer combination therapy

AstraZeneca has signed a deal with US group G1 Therapeutics to test the potential of a new combination therapy for lung cancer. The parties have …

Continue Reading →